HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supplement Sector Private Equity, M&A Activity Set For 2014 Uptick

This article was originally published in The Tan Sheet

Executive Summary

Merger and acquisition activity is expected to rise in the supplement sector 2014, says Andre Guardi of consultancy Moss Adams LLC. Companies maturing to ”critical mass” for acquisition, international and big pharma buyers, and interest in ingredient firms are all predicted to drive M&A upward in 2014.

You may also be interested in...



In Brief

Apsen pays Nestle $215M for infant formula market licenses; UAS Labs acquired in private equity deal; health groups urge Sebelius to follow OTC Plan B order; Abbott continues emerging markets push; more news In Brief.

FDA 2015 Budget Increase Proposal Leans On Food Safety User Fees

Food safety programs would get the largest increase in the White House’s proposed fiscal 2015 FDA budget, and increases in user fee programs are proposed as key drivers for the boost. The agency’s overall budget would grow $335 million to $4.7 billion in the proposal.

FDA 2015 Budget Increase Proposal Leans On Food Safety User Fees

Food safety programs would get the largest increase in the White House’s proposed fiscal 2015 FDA budget, and increases in user fee programs are proposed as key drivers for the boost. The agency’s overall budget would grow $335 million to $4.7 billion in the proposal.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

RS139461

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel